Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs Nuscale Power Corporation — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B), while Nuscale Power Corporation trades at $7.19 (market cap $3.00B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 8.4× Nuscale Power Corporation's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 1 Days and Nuscale Power Corporation for 29 Days on average.
| RPRX | SMR | |
|---|---|---|
Market Cap | $25.27B | $3.00B |
Volume | 3,671,183 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $63.96 | $53.43 |
52-Week Low | $35.44 | $7.32 |
Typical Hold Time | 1 Days | 29 Days |
Enterprise Value | $32.50B | $1.93B |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NuScale Power (SMR) trades at $7.20, down 6.13% with bearish technical signals. The company shows concerning fundamentals with negative net income margins (-3,888.7% in 2026) despite analyst consensus of $11.25 price target. Recent news highlights ongoing investor investigations and competitive pressures in the nuclear energy sector.
While analysts maintain 50% buy ratings, significant operational losses and cash burn create substantial risk. The stock faces headwinds from execution challenges and dilution concerns, though long-term nuclear energy adoption trends provide potential upside for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
